Tryptamine Therapeutics announced patient recruitment for the world’s first trial treating Binge Eating Disorder (BED) using TRP-8803, its lead program. TRP-8803 is a proprietary formulation of IV-infused psilocin that addresses the psychological and biological aspects of eating disorders.  

Early research found that TRP-8803 demonstrated an average reduction in binge eating episodes of more than 80%. First dosing of this latest trial is expected to begin this quarter, with results scheduled for Q4. 

BED is the most common eating disorder in the U.S., and globally, the BED treatment market is expected to be valued at $1.28 billion by 2031. Here’s more: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02969075-6A1273801&v=4a466cc3f899e00730cfbfcd5ab8940c41f474b6

A new study published in the journal Cell has indicated that two specific cancer drugs may help lower the risk of Alzheimer’s disease. 

According to researchers from University of California, San Francisco, the combination of letrozole (designed to treat breast cancer) and irinotecan (designed to treat colon and lung cancer) can improve memory and brain function in aging mice that show signs of dementia. You can check out the details of the study here: https://www.cell.com/cell/fulltext/S0092-86742500737-8

A new study published in Science Advances has found that a specific brain circuit that drives negative emotions during cocaine withdrawal also plays a key role in relapse. 

Researchers from The Hebrew University found that this “anti-reward” network becomes hyperactive during abstinence, amplifying distress, and pushing users back toward the drug.

Interestingly, this circuit may also serve as a protective brake by making drug use emotionally costly. 

While most current addiction therapies aim to dampen the brain’s reward system, this study points to a different path: targeting the emotional pain of withdrawal. By understanding and potentially modulating the brain’s aversive signals, future treatments may better address the root causes of relapse. Here’s more: https://www.science.org/doi/10.1126/sciadv.adu6074 

Did you know that green space can lower developmental risks?

According to a recent study published in the journal Environmental International, children exposed to more green spaces before birth and during early childhood have a lower risk of neurodevelopmental disorders, such as ADHD, autism, and learning delays. 

The dataset consisted of more than 1.8 million racially and socioeconomically diverse mother–child pairs in multiple states.

According to senior author of the study, Stefania Papatheodorou, researchers observed protective associations between residential green space and several neurodevelopmental outcomes across distinct exposure windows – preconception, prenatal, and early childhood – suggesting the involvement of different underlying biological mechanisms.

Prenatal exposure was linked to a lower risk of autism spectrum disorder, while preconception exposure was inversely associated with intellectual disability. Early childhood exposure to green space was also shown to be protective against learning difficulties. Here’s more: https://www.sciencedirect.com/science/article/pii/S0160412025004179?via%3Dihub